Breast Cancer — Metastatic

Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)

1000 KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

Javier Cortes, David W. Cescon, Hope S. Rugo, et al.
 
The abstract concludes: 
Pembro combined with several chemo partners showed a statistically significant and clinically meaningful improvement in PFS vs chemo alone in pts with previously untreated locally recurrent inoperable or metastatic TNBC whose tumors expressed PD-L1 (CPS ≥10). Pembro + chemo was generally well tolerated, with no new safety concerns.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Priyanka Sharma, Eve Rodler, William E. Barlow, et al. 
 
The abstract concludes:
The addition of Vel to cisplatin significantly improved PFS and showed a trend towards improved OS for BRCA-like advanced TNBC. Integral biomarkers used in this study identified a subgroup of BRCAwt TNBC who benefited from addition of PARPi to cisplatin; platinum plus PARPi combination should be explored further in BRCA-like TNBC. Clinical trial information: NCT02595905.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Nadine M. Tung, Mark E. Robson, Steffen Ventz, et al.
 
The abstract concludes:
In this proof-of-principle study, single-agent olaparib successfully met its primary endpoint in both cohorts. Activity was seen largely in patients with MBC and sBRCA1/2 or gPALB2 mutations but not with ATM or CHEK2 mutations. Clinical trial information: NCT03344965.

---------------------------------------------------------------------------------------------------------------------------------------------------------

 
Binghe Xu, Min Yan, Fei Ma, et al.
 
The abstract concludes:
In pts with HER2+ MBC after trastuzumab and chemo, pyrotinib plus capecitabine achieved a significant better PFS than lapatinib plus capecitabine, with manageable toxicity, verifying the phase 2 findings. Clinical trial information: NCT03080805.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Nancy U. Lin, Rashmi Krishna Murthy, Carey K. Anders, Vet al.
 
The abstract concludes:
In pts with heavily previously treated HER2+ MBC with BM, TUC in combination with T and C doubled the ORR-IC, reduced risk of IC progression or death by two thirds and reduced risk of death by nearly half. If approved, TUC in combination with T and C has the potential to become a new standard of care in pts with HER2+ MBC with and without BM. Clinical trial information: NCT02614794.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Hope S. Rugo, Florence Lerebours, Eva Ciruelos, et al. 
 
The abstract concludes: 
With follow-up still ongoing, BYLieve shows in a large number of pts that ALP + FUL demonstrates clinically meaningful efficacy and manageable toxicity post CDKi tx. Building on findings from SOLAR-1, BYLieve further supports use of ALP + FUL for HR+, HER2–PIK3CA-mut ABC. Clinical trial information: NCT03056755.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Antonio Llombart-Cussac, José Manuel Pérez-García, Meritxell Bellet, et al.
 
The abstract concludes: 
This study was not able to identify an improvement in PFS for PF over PL in patients with endocrine-sensitive ER[+]/HER2­ MBC. As both arms demonstrated comparable 4 years-OS, PF is a reasonable alternative to PL in this setting. Clinical trial information: NCT02491983.

--------------------------------------------------------------------------------------------------------------------------------------------------------

 
Jennifer S. Temel, Beverly Moy, Areej El-Jawahri, et al.
 
The abstract concludes: 
This novel collaborative palliative care intervention significantly improved communication and documentation regarding EOL care for women with MBC. Further work is needed to examine the effect of this care model on healthcare utilization at the end of life.

--------------------------------------------------------------------------------------------------------------------------------------------------------